BiotechTube

NKX019 + Fludarabine, Cyclophosphamide

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Nephritis

Conditions

Lupus Nephritis, Primary Membranous Nephropathy

Trial Timeline

Jun 13, 2024 → Apr 1, 2027

NCT ID
NCT06557265

About NKX019 + Fludarabine, Cyclophosphamide

NKX019 + Fludarabine, Cyclophosphamide is a phase 1/2 stage product being developed by Nkarta for Lupus Nephritis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06557265. Target conditions include Lupus Nephritis, Primary Membranous Nephropathy.

What happened to similar drugs?

8 of 20 similar drugs in Lupus Nephritis were approved

Approved (8) Terminated (7) Active (7)
✅tacrolimusAstellas PharmaApproved
✅Rosuvastatin + SimvastatinAstraZenecaApproved
✅AnifrolumabAstraZenecaApproved
✅BMS-986165Bristol Myers SquibbApproved
✅versus hydroxychloroquineSanofiApproved
✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved
✅Placebo plus standard therapy + Belimumab 10 mg/kg plus standard therapy + Standard therapyGSK plcApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06557265Phase 1/2Recruiting

Competing Products

20 competing products in Lupus Nephritis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
32
Baricitinib + PlaceboEli LillyPhase 2
35
DS-7011a + PlaceboDaiichi SankyoPhase 1
29
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
32
tacrolimusAstellas PharmaPhase 3
40
TacrolimusAstellas PharmaPre-clinical
26
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
32
tacrolimusAstellas PharmaApproved
35
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
40
E6742EisaiPhase 1/2
32
Baricitinib + PlaceboEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
40
LY3361237 + PlaceboEli LillyPhase 2
27
LY2127399 + PlaceboEli LillyPhase 3
32
LY3361237 + PlaceboEli LillyPhase 1
29
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
40
Baricitinib + PlaceboEli LillyPhase 3
32
LY3471851 + PlaceboEli LillyPhase 1
29
LY3471851 + PlaceboEli LillyPhase 2
35